Of the nine patients with PAH at baseline, six were receiving combination therapy (four with phosphodiesterase 5 inhibitors [PDE5is] combined with endothelin receptor antagonists [ERAs], one with calcium channel blockers combined with PDE5is and ERAs, and one with angiotensin‐converting enzyme inhibitors combined with PDE5is) and three single therapy (two receiving ERAs and one receiving intravenous iloprost) based on patients’ tolerability and in line with the current standard of care in the United Kingdom at the time of the analysis. This evidence concerns the gene ACE and pulmonary arterial hypertension.